| 6.28 0.2 (3.29%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.67 | 1-year : | 8.16 |
| Resists | First : | 6.56 | Second : | 6.98 |
| Pivot price | 6.17 |
|||
| Supports | First : | 5.88 | Second : | 4.9 |
| MAs | MA(5) : | 6.21 |
MA(20) : | 6.19  |
| MA(100) : | 6.33 |
MA(250) : | 5.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 33.9 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 7.59 | Low : | 3.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ICCC ] has closed below upper band by 33.7%. Bollinger Bands are 46.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.33 - 6.38 | 6.38 - 6.41 |
| Low: | 5.87 - 5.91 | 5.91 - 5.94 |
| Close: | 6.02 - 6.09 | 6.09 - 6.14 |
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Thu, 06 Nov 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 - MarketScreener
Thu, 06 Nov 2025
ImmuCell (NASDAQ: ICCC) schedules third-quarter results for Nov 13; call Nov 14 - Stock Titan
Tue, 04 Nov 2025
ImmuCell Announces New CEO and Leadership Changes - TipRanks
Tue, 04 Nov 2025
ImmuCell appoints Olivier te Boekhorst as new CEO - Investing.com
Tue, 04 Nov 2025
ImmuCell Corporation Announces Appointment of New CEO Olivier te Boekhorst and Board Changes - Quiver Quantitative
Tue, 04 Nov 2025
ImmuCell (NASDAQ: ICCC) names Olivier te Boekhorst CEO, effective Nov 1, 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 27.8 (%) |
| Held by Institutions | 19.9 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | 0.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.29 |
| Profit Margin | 6.2 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 3 % |
| Return on Equity (ttm) | 6.6 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 1.21 |
| Sales Per Share | 3.12 |
| EBITDA (p.s.) | 0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 29.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 2 |
| Price to Cash Flow | 22.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|